T2 Biosystems, Inc., a leader in rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced on May 6, 2024, that it has entered into an exclusive distribution agreement in Qatar. This agreement allows T2 Biosystems to sell its T2Dx Instruments, T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel through a newly appointed distributor, marking a significant expansion of the company's commercial presence in the Middle East. The move aligns with Qatar's National Sepsis Program, which has achieved one of the world's lowest sepsis mortality rates through its prevention efforts and regular symposiums. The introduction of T2 Biosystems' products in Qatar is expected to enable faster detection of sepsis-causing pathogens and antibiotic resistance genes, aiding clinicians in providing timely and targeted therapy. John Sperzel, Chairman and CEO of T2 Biosystems, expressed the company's commitment to global commercialization and the importance of the Middle East in their international strategy. The company anticipates strong growth potential in the region and aims to improve patient care quality for those at risk of sepsis.

T2 Biosystems, Inc., a leader in rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced on May 6, 2024, that it has entered into an exclusive distribution agreement in Qatar. This agreement allows T2 Biosystems to sell its T2Dx Instruments, T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel through a newly appointed distributor, marking a significant expansion of the company's commercial presence in the Middle East. The move aligns with Qatar's National Sepsis Program, which has achieved one of the world's lowest sepsis mortality rates through its prevention efforts and regular symposiums. The introduction of T2 Biosystems' products in Qatar is expected to enable faster detection of sepsis-causing pathogens and antibiotic resistance genes, aiding clinicians in providing timely and targeted therapy. John Sperzel, Chairman and CEO of T2 Biosystems, expressed the company's commitment to global commercialization and the importance of the Middle East in their international strategy. The company anticipates strong growth potential in the region and aims to improve patient care quality for those at risk of sepsis.